{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T04:40:13Z","timestamp":1648615213097},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00345-018-2468-3","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T08:44:36Z","timestamp":1535618676000},"page":"1699-1701","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy for bladder cancer: the fight is on"],"prefix":"10.1007","volume":"36","author":[{"given":"Morgan","family":"Roupr\u00eat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"key":"2468_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","volume":"69","author":"J Leal","year":"2016","unstructured":"Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA (2016) Economic burden of bladder cancer across the European union. Eur Urol 69:438\u2013447. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2015.10.024","journal-title":"Eur Urol"},{"key":"2468_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"key":"2468_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447\u2013461. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"key":"2468_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.09.002","author":"K Hendricksen","year":"2017","unstructured":"Hendricksen K, Aziz A, Bes P et al (2017) Discrepancy between european association of urology guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey. Eur Urol Focus. \n                    https:\/\/doi.org\/10.1016\/j.euf.2017.09.002","journal-title":"Eur Urol Focus"},{"key":"2468_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"J Alfred Witjes","year":"2017","unstructured":"Alfred Witjes J, Lebret T, Comp\u00e9rat EM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462\u2013475. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.06.020","journal-title":"Eur Urol"},{"key":"2468_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2334-3","author":"J Falke","year":"2018","unstructured":"Falke J, Hulsbergen-van de Kaa CA, Maj R et al (2018) A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model. World J Urol. \n                    https:\/\/doi.org\/10.1007\/s00345-018-2334-3","journal-title":"World J Urol"},{"key":"2468_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.10.003","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Li R, O\u2019Donnell MA et al (2017) Predicting response to intravesical bacillus Calmette\u2013Gu\u00e9rin immunotherapy: Are we there yet? A systematic review. Eur Urol. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2017.10.003","journal-title":"Eur Urol"},{"key":"2468_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2313-8","author":"L Lenfant","year":"2018","unstructured":"Lenfant L, Verhoest G, Campi R et al (2018) Perioperative outcomes and complications of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy for bladder cancer: a real-life, multi-institutional French study. World J Urol. \n                    https:\/\/doi.org\/10.1007\/s00345-018-2313-8","journal-title":"World J Urol"},{"key":"2468_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00345-011-0798-5","volume":"31","author":"DR Yates","year":"2013","unstructured":"Yates DR, Roupr\u00eat M (2013) Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response. World J Urol 31:117\u2013125. \n                    https:\/\/doi.org\/10.1007\/s00345-011-0798-5","journal-title":"World J Urol"},{"key":"2468_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2332-5","author":"M Rouanne","year":"2018","unstructured":"Rouanne M, Roumigui\u00e9 M, Hou\u00e9d\u00e9 N et al (2018) Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J Urol. \n                    https:\/\/doi.org\/10.1007\/s00345-018-2332-5","journal-title":"World J Urol"},{"key":"2468_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2264-0","author":"F Soria","year":"2018","unstructured":"Soria F, Beleni AI, D\u2019Andrea D et al (2018) Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol. \n                    https:\/\/doi.org\/10.1007\/s00345-018-2264-0","journal-title":"World J Urol"},{"key":"2468_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2354-z","author":"L-M Krabbe","year":"2018","unstructured":"Krabbe L-M, Margulis V, Schrader AJ et al (2018) Molecularly-driven precision medicine for advanced bladder cancer. World J Urol. \n                    https:\/\/doi.org\/10.1007\/s00345-018-2354-z","journal-title":"World J Urol"},{"key":"2468_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupr\u00eat","year":"2018","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00e9rat E et al (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73:111\u2013122. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2017.07.036","journal-title":"Eur Urol"},{"key":"2468_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2369-5","author":"C Ringuette-Goulet","year":"2018","unstructured":"Ringuette-Goulet C, Bolduc S, Pouliot F (2018) Modeling human bladder cancer. World J Urol. \n                    https:\/\/doi.org\/10.1007\/s00345-018-2369-5","journal-title":"World J Urol"},{"key":"2468_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2371-y","author":"SA Fletcher","year":"2018","unstructured":"Fletcher SA, Harmouch SS, Krimphove MJ et al (2018) Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World J Urol. \n                    https:\/\/doi.org\/10.1007\/s00345-018-2371-y","journal-title":"World J Urol"},{"key":"2468_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2359-7","author":"F Audenet","year":"2018","unstructured":"Audenet F, Farkas AM, Anastos H et al (2018) Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. World J Urol. \n                    https:\/\/doi.org\/10.1007\/s00345-018-2359-7","journal-title":"World J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2468-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2468-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2468-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T23:33:15Z","timestamp":1567121595000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2468-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["2468"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2468-3","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]},"assertion":[{"value":"30 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}